The obscure advisory committees at the heart of the U.S. drug pricing debate CarolineHumer reports
CHICAGO - Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries.
They concluded that all three medicines offered no clear benefit over drugs already on the market and that insurers could consider them optional when it came to health coverage. They advised putting limits into place on their use. These relatively unknown expert committees have been involved in drug coverage decisions for decades. Their members’ identities are kept secret due to federal regulations aimed at preventing pharmaceutical industry interference.
Their decisions have new consequences as the pharmacy benefits companies they advise are more likely to exclude a new treatment from coverage if it is deemed on par with existing therapies. Or they can demand discounts - or rebates - from drugmakers in exchange for the coverage. U.S. Congress and President Donald Trump have taken up that criticism, and the administration has proposed banning rebates in government health programs unless benefits managers hand over the savings to patients.
Migraines affect more than 39 million Americans, mostly women, and Amgen estimated 8 million could be candidates for the preventative therapies, which are delivered by injection every month or few months. Analysts forecast $4 billion in annual sales by 2026 in major global markets. “Let’s be cautious and see how it all plays out, but we need to look at these studies with a jaundiced eye,” one of the members said.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
AbbVie's Skyrizi drug to treat psoriasis wins U.S. approvalAbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved i...
Lire la suite »
U.S. brings first criminal case against major drug distributor over opioidsThe U.S. government on Tuesday filed its first criminal charges against a major ...
Lire la suite »
10 leaders transforming healthcare shared the biggest misconceptions about their industry, from drug prices to psychedelicsNot everyone in healthcare is looking out for you, one leader told us. Also, not all psychedelic drugs work the same, and there's more to the Crispr controversy.
Lire la suite »
The Health 202: Trump needs help from Pelosi to notch a big drug pricing winPresident Trump needs help from Pelosi to notch a big drug pricing win
Lire la suite »
Halliburton says pricing woes bottoming out as U.S. activity risesHalliburton Co said on Monday a pricing downturn that has plagued the oilfield s...
Lire la suite »
U.S. to end all waivers on imports of Iranian oil, crude price jumpsThe United States on Monday demanded that buyers of Iranian oil stop purchases b...
Lire la suite »
Lawsuit says Tyson, Cargill, JBS conspired to suppress beef prices paid to U.S. ranchersFour of the largest U.S. beef-packing companies were accused in a lawsuit on Tue...
Lire la suite »
U.S. new-home sales climbed 4.5% in March, and prices sankThe U.S. housing market appears to be cautiously recovering from a mortgage-rate spike last year that caused homebuying to slump.
Lire la suite »
U.S. new home sales hit one-and-a-half-year high on lower mortgages, pricesSales of new U.S. single-family homes rose to a near 1-1/2-year high in March, b...
Lire la suite »